Pyruvate Kinase M2 Expression, but Not Pyruvate Kinase Activity, Is Up-Regulated in a Grade-Specific Manner in Human Glioma
暂无分享,去创建一个
Shichun Zheng | Joydeep Mukherjee | Sabrina M. Ronen | J. Wiencke | R. Pieper | J. Phillips | S. Ronen | Shichun Zheng | Joanna J. Phillips | J. Mukherjee | John Wiencke | Russell O. Pieper | S. Zheng
[1] A. Guha,et al. Targeting Metabolic Remodeling in Glioblastoma Multiforme , 2010, Oncotarget.
[2] R. Bamezai,et al. Human pyruvate kinase M2: A multifunctional protein , 2010, Protein science : a publication of the Protein Society.
[3] B. Kefas,et al. Pyruvate kinase M2 is a target of the tumor-suppressive microRNA-326 and regulates the survival of glioma cells. , 2010, Neuro-oncology.
[4] K. Aldape,et al. Nuclear PKM2 regulates β-catenin transactivation upon EGFR activation , 2011, Nature.
[5] Eric A Bushong,et al. Dedifferentiation of Neurons and Astrocytes by Oncogenes Can Induce Gliomas in Mice , 2012, Science.
[6] L. Cantley,et al. Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation , 2009, Science.
[7] Z. Hall. Cancer , 1906, The Hospital.
[8] Steven Eschrich,et al. Molecular and Cellular Pathobiology The Metabolomic Signature of Malignant Glioma Re fl ects Accelerated Anabolic Metabolism , 2012 .
[9] J. Manley,et al. Turning on a fuel switch of cancer: hnRNP proteins regulate alternative splicing of pyruvate kinase mRNA. , 2010, Cancer research.
[10] M. Assanah,et al. HnRNP proteins controlled by c-Myc deregulate pyruvate kinase mRNA splicing in cancer , 2010, Nature.
[11] C. Boschek,et al. Pyruvate kinase type M2 and its role in tumor growth and spreading. , 2005, Seminars in cancer biology.
[12] B. Davidson,et al. Tumour M2-pyruvate kinase: a gastrointestinal cancer marker , 2007, European journal of gastroenterology & hepatology.
[13] Russell G. Jones,et al. Tumor suppressors and cell metabolism: a recipe for cancer growth. , 2009, Genes & development.
[14] L. Parada,et al. Malignant Glioma: Lessons from Genomics, Mouse Models, and Stem Cells , 2012, Cell.
[15] Xueliang Gao,et al. Pyruvate kinase M2 regulates gene transcription by acting as a protein kinase. , 2012, Molecular cell.
[16] S. Baker,et al. The PTEN/Akt pathway dictates the direct alphaVbeta3-dependent growth-inhibitory action of an active fragment of tumstatin in glioma cells in vitro and in vivo. , 2006, Cancer research.
[17] Lynda Chin,et al. Emerging insights into the molecular and cellular basis of glioblastoma. , 2012, Genes & development.
[18] O. Warburg. [Origin of cancer cells]. , 1956, Oncologia.
[19] M. Brada. Pathology and Genetics of Tumours of the Nervous System , 2001, British Journal of Cancer.
[20] Jason W. Locasale,et al. Evidence for an Alternative Glycolytic Pathway in Rapidly Proliferating Cells , 2010, Science.
[21] A. Levine,et al. The Control of the Metabolic Switch in Cancers by Oncogenes and Tumor Suppressor Genes , 2010, Science.
[22] S. J. Darnton,et al. The metabolic marker tumour pyruvate kinase type M2 (tumour M2-PK) shows increased expression along the metaplasia–dysplasia–adenocarcinoma sequence in Barrett’s oesophagus , 2004, Journal of Clinical Pathology.
[23] T. Tanaka,et al. The M1- and M2-type isozymes of rat pyruvate kinase are produced from the same gene by alternative RNA splicing. , 1986, The Journal of biological chemistry.
[24] M. Gumińska,et al. Tumor-specific pyruvate kinase isoenzyme M2 involved in biochemical strategy of energy generation in neoplastic cells. , 1997, Acta biochimica Polonica.
[25] J. Nakamura,et al. S6K1 plays a key role in glial transformation. , 2008, Cancer research.
[26] F. Rösl,et al. Alternative splicing of human papillomavirus type-16 E6/E6* early mRNA is coupled to EGF signaling via Erk1/2 activation , 2010, Proceedings of the National Academy of Sciences.
[27] P. Mischel,et al. Metabolic state of glioma stem cells and nontumorigenic cells , 2011, Proceedings of the National Academy of Sciences.
[28] G. Semenza,et al. Oncogenic alterations of metabolism. , 1999, Trends in biochemical sciences.
[29] O. Mirzoeva,et al. The Mre11/Rad50/Nbs1 complex interacts with the mismatch repair system and contributes to temozolomide-induced G2 arrest and cytotoxicity , 2006, Molecular Cancer Therapeutics.
[30] B. Christensen,et al. DNA methylation, isocitrate dehydrogenase mutation, and survival in glioma. , 2011, Journal of the National Cancer Institute.
[31] Ru Wei,et al. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth , 2008, Nature.
[32] G. Semenza. Oxygen sensing, homeostasis, and disease. , 2011, The New England journal of medicine.
[33] G. Semenza. mechanisms of disease Oxygen Sensing , Homeostasis , and Disease , 2011 .
[34] W. Zwerschke,et al. Effects of the human papilloma virus HPV-16 E7 oncoprotein on glycolysis and glutaminolysis: role of pyruvate kinase type M2 and the glycolytic-enzyme complex. , 2001, The Biochemical journal.
[35] F. Ducray,et al. IDH1 and IDH2 mutations in gliomas. , 2009, The New England journal of medicine.
[36] H. Lehrach,et al. No evidence for a shift in pyruvate kinase PKM1 to PKM2 expression during tumorigenesis , 2011, Oncotarget.
[37] D. Gisselsson,et al. Glial Progenitor-Like Phenotype in Low-Grade Glioma and Enhanced CD133-Expression and Neuronal Lineage Differentiation Potential in High-Grade Glioma , 2008, PloS one.
[38] D. Sabatini,et al. Cancer Cell Metabolism: Warburg and Beyond , 2008, Cell.
[39] F. Oesch,et al. Expression of pyruvate kinase M2 in preneoplastic hepatic foci of N-nitrosomorpholine-treated rats , 1999, Virchows Archiv.
[40] Y. Wang,et al. Shikonin and its analogs inhibit cancer cell glycolysis by targeting tumor pyruvate kinase-M2 , 2011, Oncogene.
[41] S. Schreiber,et al. Perturbational profiling of a cell-line model of tumorigenesis by using metabolic measurements , 2005, Proceedings of the National Academy of Sciences of the United States of America.